MedTrace Logo

A Study for Post-Marketing Surveillance of Niraparib in the Treatment of Adult Participants for Approved Indications in South Korea

NCT04589039 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 662

Last updated 2024-12-11

No results posted yet for this study

Summary

The purpose of this study is to estimate the cumulative incidence of all adverse events (AEs), including serious adverse events (SAEs), adverse event of special interest (AESI), among participants who have been administered niraparib as per the approved indications.

Conditions

  • Ovarian Neoplasms

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Takeda

Eligibility

Min Age
19 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-16
Primary Completion
2024-09-11
Completion
2024-09-11

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04589039 on ClinicalTrials.gov